| 1 Global state: 1. clinical improvement (as defined by each study) |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.1 medium term |
1 |
220 |
Risk Ratio (M‐H, Random, 95% CI) |
4.73 [1.06, 21.11] |
| 2 Leaving the study early: 1. any reason |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.1 medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.39 [0.25, 0.60] |
| 3 Leaving the study early: 2. severe adverse effects |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 3.1 medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.33 [0.03, 3.10] |
| 4 Leaving the study early: 3. due to relapse or worsening |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1 medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.39 [0.25, 0.61] |
| 5 Extrapyramidal adverse effects: 2. akathisia |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 5.1 short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
6.88 [1.60, 29.56] |
| 6 Extrapyramidal adverse effects: 3. Parkinsonism |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 6.1 short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.69 [0.35, 1.38] |
| 7 Extrapyramidal adverse effects: 4. dystonia |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 7.1 short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.98 [0.44, 2.17] |
| 8 Other adverse effects: 2. specific |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 8.1 decreased appetite ‐ short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.60 [0.36, 1.00] |
| 8.2 dizziness/faintness ‐ short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
6.88 [0.36, 131.62] |
| 8.3 drowsiness ‐ short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.98 [0.33, 2.95] |
| 8.4 fainting ‐ short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
4.91 [0.58, 41.37] |
| 8.5 hypotension ‐ short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
1.47 [0.79, 2.75] |
| 8.6 insomnia ‐ short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.65 [0.24, 1.78] |
| 8.7 nausea/ vomiting ‐ short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.42 [0.11, 1.59] |
| 8.8 photosensitivity ‐ short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.65 [0.11, 3.84] |
| 8.9 seizures ‐ short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.33 [0.01, 7.95] |
| 8.10 skin rashes ‐ short/medium term |
1 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.98 [0.20, 4.76] |
